Antiplatelet therapy following drug-eluting stent implantation: New clinical data and recommendations

Minerva Cardioangiologica

Volumn 56, Issue 1, 2008, Pages 139-154

  Paradis, J M ^a   Ducrocq, G ^a   Tanguay, J F ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Drug eluting stents; Platelet aggregation inhibitors; Thienopyridine; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 3A4; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; PLACEBO; PRASUGREL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; LONG TERM CARE; MAINTENANCE DRUG DOSE; MONOTHERAPY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CANADA; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EUROPE; HUMANS; ITALY; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 42049094410     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation 1964;30;654-70.
2. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. New Engl J Med 1979;301:61-8.
3. Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable intraluminal graft: a preliminary study: work in progress. Radiology 1985;156:73-7.
4. Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. Circulation 1987;76:450-7.
5. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. New Engl J Med 1987;316:701-6.
6. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. New Engl J Med 1994;331:489-95.
7. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Perm I et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. New Engl J Med 1994;331:496-501.
8. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al; for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. New Engl J Med 1998; 339:1665-71.
9. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
10. Serruys PW, Kutryk MJB, Ong ATL. Coronary-Artery Stents. New Engl J Med 2006;354:483-95.
11. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents. J Am Coll Cardiol 2005;45:2088-92.
12. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
13. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D et al. TAXUS V Investigators.. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
14. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. N Engl J Med 2007;356:998-1008.
15. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. N Engl J Med 2007;356:1030-9.
16. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA et al. EVENT Registry Investigators. Clinical Outcomes and Stent Thrombosis Following Off-label Use of Drug-Eluting Stents. JAMA 2007;297:2001-9.
17. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents versus bare-metal stents. J Am Coll Cardiol 2006;48:84-91.
18. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of Drug-Eluting Stents in Humans. J Am Coll Cardiol 2006;48:193-202.
19. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents. J Am Coll Cardiol 2006;47:2108-11.
20. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
21. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-2.
22. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. An intravascular ultrasound study. J Am Coll Cardiol 2005;45:995-8.
23. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-6.
24. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M et al. Drug-eluting stent thrombosis: result from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9.
25. Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rodriguez-Alemparte M, Berrocal D et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III Trial. J Am Coll Cardiol 2006;47:205-7.
26. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L et al. Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. Circulation 2007;116:745-54.
27. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosi of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
28. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
29. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA et al. Clinical End Points in Coronary Stent Trials. Circulation 2007;115:2344-51.
30. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.
31. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
32. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92:641-9.
33. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J. Safety of Coronary Sirlimus-Eluting Stents in Daily Clinical Practice. Circulation 2006;113:1434-41.
34. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K et al. Thirty day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
35. Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD et al. Thrombosis and Drug-Eluting Stents. J Am Coll Cardiol 2007;50:109-18.
36. The Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
37. The ISIS-2 Investigators. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction: ISIS-2. ISIS-2 Collaborative group. Lancet 1988;2:349-60.
38. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-603.
39. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
40. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA et al. Variability in Individual Responsiveness to Clopidogrel. J Am Coll Cardiol 2007;49:1505-16.
41. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
42. Steinhubl SR, Berger PB, Brennan DM, Topol EJ; CREDO Investigators. Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. J Am Coll Cardiol 2006;47:939-43.
43. Mehta SR, Yusuf S. Peters RJ, Bertrand ME, Lewis BS, Natarajan MK et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCl-CURE study. Lancet 2001;358:527-33.
44. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D. Sardella G. Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA (Antiplatelet therapy for reduction of myocardial damage during angioplasty)-2 Study. Circulation 2005;111:2099-106.
45. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13.
46. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51.
47. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA_et al. Variability in Individual Responsiveness to Clopidogrel. Clinical Implications, Management, and Future Perspectives. J Am Coll Cardiol 2007;49:1505-16.
48. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R et al. Impact of Platelet reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. J Am Coll Cardiol 2007;49:2312-7.
49. Steinhubl S, Roe MT. Optimizing P2Y12 inhibition in patients undergoing PCI. Cardiovasc Drug Rev 2007;25:188-203.
50. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-15.
51. Bhatt DL. Intensifying Platelet Inhibition-Navigating between Scylla and Charybdis. N Engl J Med 2007;357:2078-81.
52. Lembo NJ, Black AJ, Roubin GS, Wilentz JR, Mufson LH, Douglas JS Jr et al. Effect of pretreatment with aspirin vs aspirin plus dypiridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422-6.
53. Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y et al. coronary stent implantation. Clin Ther 1997;19:1058-66.
54. Ahn JC, Song WH, Kwon JA, Park CG, Seo HS, Oh DJ et al. Effects of cilostazol on platelet activation in coronary stenting patients who are already treated with aspirin and clopidogrel. Korean J Intern Med 2004;19:230-6.
55. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005;46:1833-7.
56. Husted S, Emanuelsson H, Heptinstall S, Sandset PM. Wickens M, Peters G et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD 6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47.
57. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/SCAI writing committee to update 2001 guidelines for percutaneous coronary intervention). Circulation 2006;113:e166-e286.
58. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
59. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement. Circulation 2006;113:2803-9.
60. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ et al. American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. Circulation 2007;115;813-8.
61. Love MP, Schampaert E, Cohen EA, Webb JG, Anderson TJ, Labinaz M et al. Canadian Association of Interventional Cardiology; Canadian Cardiovascular Society. The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. Can J Cardiol 2007;23:121-3.
62. Braunwald E, Zipes DP, Libby P, Bonow R. Braunwald's Heart Disease. A textbook of cardiovascular medicine. 7th ed. St. Louis, MO; Elsevier; 2005. p. 1142.
63. Ducrocq G, Serebruany V, Tanguay JF. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. Expert Rev Cardiovasc Ther 2007;5:939-53.